logo-loader
Eden BioSolutions

Eden Research plc - Thymolflex EPA approval

RNS Number : 1487Z
Eden Research plc
02 April 2026
 

As the information in this release pertains to EDEN RESEARCH PLC, this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR"), which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

2 April 2026

 

Eden Research PLC - AnnualReports.com

 

Eden Research Plc

("Eden" or "Company")

 

Thymolflex® EPA approval

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technologies, is pleased to announce that the Company's partner, Véto-pharma, has received regulatory approval from the US Environmental Protection Agency ("EPA") for Thymolflex® for use in integrated Varroa management. Thymoflex® is a thymol-based treatment used in bee health to control Varroa destructor, an external parasitic mite that attacks and feeds on honey bees. This approval follows an announced agreement, signed by the Company in April 2025, to supply Véto-pharma with thymol for use in bee care products.

 

Supporting integrated Varroa management strategies

 

Varroa destructor remains one of the most significant threats to honey bee health worldwide. As resistance concerns increase and environmental conditions become more unpredictable, beekeepers need multiple authorised tools that can be adapted to different colony conditions and management systems.

 

Thymoflex® is based on thymol, a well-known active substance of natural origin, widely used by beekeepers as part of integrated pest management (IPM) programs.

 

Thymoflex® is a ready-to-use thymol gel designed for straightforward handling and application in the apiary. The product allows for a controlled release of thymol within the hive, contributing to effective mite control when used according to label directions. Its formulation aims to combine ease of use, consistency, and colony safety, making it suitable for professional beekeeping operations.

 

By expanding access to thymol-based solutions, Thymoflex® offers beekeepers an additional option to:

·      A treatment based on a naturally derived active substance

·      Flexible use within the beekeeping season, according to label instructions

·      Reduce reliance on a single mode of action

·      Proven efficacy against varroa, including in the presence of brood

·      Compatibility with treatment rotation programs, helping to manage resistance risks

·      Enhance grooming behaviour and overall hygienic responses in honey bee colonies.

 

The gel formulation enables a homogeneous diffusion of thymol within the hive, contributing to colony safety when used according to label directions.

 

Availability

 

Thymoflex® has received EPA federal approval and will be made available to beekeepers in the United States in accordance with individual state registrations.

 

More information about Thymoflex® will be available soon on the Véto-pharma website: https://www.veto-pharma.com

 

A long-standing commitment to honey bee health

Honeybee health is affected by multiple factors, including climate change, habitat loss, nutritional stress, pesticide exposure, and pathogens, among which varroa plays a central role. Addressing these challenges requires robust, flexible, and science-based solutions.

 

For more than 25 years, Véto-pharma has focused exclusively on honey bee health, developing and manufacturing products designed to support beekeepers worldwide in protecting their colonies and securing the future of pollination.

 

Sean Smith, CEO of Eden Research, commented:

 

"We are delighted to be able to play such a key role in the delivery of vital care products to keep bee populations thriving. Our partnership with Véto-pharma is representative of our commitment to diversifying our business model and revenue streams by applying our sustainable chemical technology to other sectors beyond arable agriculture."

 

-- ENDS --

 

For further information, contact:

 

Eden Research plc

www.edenresearch.com

Sean Smith
Alex Abrey

 

 

01285 359 555



Cavendish Capital Markets Limited (Nominated advisor and joint broker)


Giles Balleny / Elysia Bough (Corporate Finance)

Harriet Ward (Corporate Broking)
Dale Bellis (Sales)

 

 

020 7220 0500



Oberon Capital (Joint Broker)

020 3179 5300

Nick Lovering

Mike Seabrook

Adam Pollock

 


Hawthorn Advisors (Financial PR)


Jamie Plotnek

 

eden@hawthornadvisors.com

 

 

Notes to Editors:

 

About Eden Research

 

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

For more information about Eden, visit:  www.edenresearch.com.

 

Follow Eden on LinkedIn, Twitter and YouTube. 

About Véto-pharma

Founded in 1982, Véto-pharma is a veterinary pharmaceutical laboratory dedicated to honey bee health. The company is recognised globally for its expertise, innovation, and high-quality products developed and manufactured in France.

For more information about Véto-pharma, visit: https://www.veto-pharma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
REAIBMRTMTMMBAF
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Eden Research CEO talks revenue growth and latest Ecovelex regulatory win

Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) CEO Sean Smith talked with Proactive's Stephen Gunnion about recent developments, including the company's growth and new regulatory achievements. Smith highlighted the second consecutive approval for Ecovelex in Italy, an important product in their...

on 11/08/2024

5 min read